THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth announced today that it will sponsor the 2014 Cancer Center Business Summit. Organized by a national advisory board of oncology thought leaders and co-hosted by the American Society of Clinical Oncology, the summit will take place November 6 -7, 2014 in Chicago, Ill.
This year’s theme, “Building the Oncology System of the Future: Transforming Patient Care Data Transparency and Analytics,” will be explored during the summit’s presentations of original research, panels and breakout sessions led by its faculty of industry leaders. The summit will address the most important issues currently facing cancer care providers, focusing on how innovation in business can be used to create a better oncology system.
Included in the summit’s agenda are the topics of personalized medicine and actionable data analytics, which are both key to MolecularHealth’s mission: to advance the science of applying intelligent analytics to cancer treatment. The company’s TreatmentMAP™ solution provides a best-in-class software and diagnostic platform for molecular interpretation, drug safety and unique treatment decision support for oncologists and each of their cancer patients.
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAP™ is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.